Ubenimex 2018-09-07T13:59:05+00:00

Clinical Trials

June 10, 2016

A Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1) (LIBERTY)

  • Study Sponsor: Eiger BioPharmaceuticals, Inc.
  • Institution: Eiger BioPharmaceuticals, Inc.
  • Start Date: April, 2016
  • End Date: Completed
  • Design: Placebo-controlled
    Background treatment allowed
  • Age range (years): from 18 to 75
  • Type of PH
    • All PAH (Group 1 PH)
  • Study Duration for individual patient: 24 weeks
  • Contact: Company Website: www.eigerbio.com; Contact info about trial: Erica McCluskey (emccluskey@eigerbio.com)
  • Listing on clinicaltrials.gov